Perceive Pharma is advancing novel small molecule neuroprotective therapeutics, with lead pipeline programs in glaucoma and other ophthalmic diseases. Perceive was founded on compelling research that leveraged a comprehensive screening process in retina cells to identify maximally neuroprotective biological pathways. The Company is backed by Deerfield Management, Johnson & Johnson Innovation, Braidwell LP, GV, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, and Catalio Capital Management, LP.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/19/25 | $15,000,000 | Series A |
Braidwell Catalio Capital Deerfield Management Company, L.P. GV Johnson & Johnson Innovation Retinal Degeneration Fund | undisclosed |
